[Major Good News] Guangzhou Weiboxin Has Secured Another “National-Level Certification”! The Porcine Circovirus Type 2 ELISA Antibody Detection Kit Has Been Granted an Approval Number!

Precision Testing · Technology Empowerment · Supporting Pig Industry Health

📢📢📢 Developed by Guangzhou Weiboxin Biotechnology Co., Ltd. Porcine Circovirus Type 2 (PCV2) ELISA Antibody Test Kit , in accordance with the Regulations on the Administration of Veterinary Drugs, the Measures for the Administration of Approval Numbers for Veterinary Drug Products, and other relevant provisions, and following review and verification of compliance, the product has been granted an approval number for veterinary drug products: Veterinary drug registration number 191438851 ！ This represents another milestone achievement for Guangzhou Weiboxin in the field of animal disease diagnostics, following the development of the African Swine Fever Virus Fluorescent PCR Detection Kit (Veterinary Drug Registration No. 191438923), the Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit (Veterinary Drug Registration No. 191438213), and the Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit (Veterinary Drug Registration No. 191438875). 
 

1. Precision and efficiency: The enzyme-linked immunosorbent assay (ELISA) with blocking inhibition is employed, achieving accuracy and specificity of up to 99% for precise quantification of antibody levels, thereby facilitating the scientific evaluation of vaccine-induced immune responses.

2. Convenient operation: Pre-coated with recombinant Porcine Circovirus Type 2 Cap protein, this assay delivers rapid results in just 45 minutes and is accompanied by dedicated data analysis software, significantly enhancing testing efficiency and data processing capabilities.

3. Stable and reliable: Certified to ISO 9001, ISO 14001, and GMP standards, the kit maintains a shelf life of up to 12 months when stored at 2–8°C, with quality rigorously validated through thousands of clinical trials. 
 

4. Worry-free service: We provide free technical guidance, sample testing services, and trial product kits to offer end-to-end support for disease prevention and control at livestock farms.

PCV2 is the primary pathogen responsible for diseases such as porcine multisystemic wasting syndrome and reproductive disorders in piglets. Guangzhou Weiboxin’s new product enables precise detection of serum antibodies, providing pig farms with: 
 

✔️ Immune efficacy assessment: Quantify antibody levels to determine the blockade rate and scientifically develop booster vaccination schedules.

✔️ Epidemic risk alert: Early detection of infected individuals to break the chain of virus transmission.

✔️ Cost optimization: reduce indiscriminate medication and improve farming profitability.

🌐 Follow the WeChat official account “Weiboxin Biotechnology” and reply with “PCV2” to receive a detailed product overview and technical white paper!

For animal disease testing reagents, please choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-66377266 / 135 3988 6748, Ms. Dai

Guangzhou Weiboxin Biotechnology Co., Ltd. is located in the national-level innovation park—Guangzhou Science City—and is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. The company is recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a provincial demonstration unit for intellectual property management. It also serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and as an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, it has been designated as an innovative, high-potential enterprise by multiple research institutes, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider.” In addition, it holds veterinary drug product approval numbers issued by the Ministry of Agriculture and Rural Affairs: Veterinary Drug Registration No. 191438923 (Fluorescent PCR Test Kit for African Swine Fever Virus), Veterinary Drug Registration No. 191438213 (ELISA Antibody Test Kit for Porcine Reproductive and Respiratory Syndrome Virus), and Veterinary Drug Registration No. 191438875 (Blocking ELISA Antibody Test Kit for Classical Swine Fever Virus). The company was awarded the Excellence Prize in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition within the Science and Technology Innovation and Entrepreneurship Contest, and the National Third Prize in the Growth Category of the National Finals of the Nanotechnology Industry Technology Innovation Special Competition at the China Innovation and Entrepreneurship Competition. It has consecutively received the A-level Tax Credit Honor Certificate, the Four-Star Trademark Brand Certification, and the Two-Integration Management System Assessment Certificate each year, as well as ISO 9001 International Quality Management System Certification and ISO 14001 International Environmental Management System Certification, and has also obtained GMP certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic–identification test kits (ZL2006). The company has also established a nationwide distribution network covering more than ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline, and innovation is our soul; we will unwaveringly uphold this philosophy as we strive to become the premier supplier of rapid diagnostic reagents and instruments.